NYSE: CLB · Oil & Gas Equipment & Services
Core Laboratories (CLB) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Core Laboratories (CLB) at $8.21 a share. The stock last closed at $8.45, which puts the model's fair value 2.8% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Core Laboratories N.V.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $7.96 to $8.21 (+3.1%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $8.45 is 2.8% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 3 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CLB?
The calibrated range for CLB over 63 trading days is $6.57 to $9.75. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $5.90 to $10.97. In 39% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector. It delivers specialised services and products for characterising subterranean reservoirs and optimising hydrocarbon extraction.
The model's fair value is $8.21 a share, the midpoint of 2,000 simulations, on the run of 14 Nov 2026. The previous run gave $7.96, so the fair value moved +3.1%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $6.57 to $9.75. It is built from the fair value, since there is no live options data for the stock. The range is calibrated weekly against realised prices, using 13,250 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
On overall quality, the business scores 56 out of 100 against comparable companies. Stability scores 100, with EBITDA margin downside volatility at 0.6 pts over 5y against a peer median of 9.4 pts. Capital discipline scores 88, with net buybacks at 2.5% of market value against a peer median of 0.0%. Growth quality scores 28, with trailing revenue growth of 0.5% against a peer median of 4.0%. The model compares it with Bristow Group Inc. (VTOL), RPC, Inc. (RES), Innovex International, Inc. (INVX), Oceaneering International, Inc. (OII), Tidewater Inc. (TDW) and Cactus, Inc. (WHD).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CLB report earnings, and how has the stock reacted?
Core Laboratories's next earnings report is scheduled for 3 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CLB's last 8 reports, ignoring direction, was 7.1%.
How does CLB score on business quality?
Core Laboratories's overall quality score is 56 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 40 | 6.0%ROIC | 4.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 77 | 1.34xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 28 | 0.5%Revenue growth, trailing | 4.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 88 | 2.5%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 41 | 2.61xNet debt / EBITDA | 2.30x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 100 | 0.6 ptsEBITDA margin downside volatility, 5y | 9.4 pts |
How does CLB compare with similar companies?
The companies in oil & gas equipment & services closest to Core Laboratories in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AESI Atlas Energy Solutions Inc. | $5.13 | $4.08 | -20.5% | Low evidence grade |
| VTOL Bristow Group Inc. | $39.59 | $39.75 | +0.4% | Fairly valued |
| RES RPC, Inc. | $5.47 | $6.59 | +20.5% | Undervalued |
| INVX Innovex International, Inc. | $24.03 | $23.20 | -3.5% | Fairly valued |
| LBRT Liberty Energy Inc. | $12.25 | $13.05 | +6.5% | Low evidence grade |
| OII Oceaneering International, Inc. | $34.21 | $34.09 | -0.4% | Fairly valued |
| TDW Tidewater Inc. | $74.94 | $74.11 | -1.1% | Fairly valued |
| WHD Cactus, Inc. | $59.75 | $58.81 | -1.6% | Fairly valued |
What the comparable companies' multiples alone would give for CLB, the peer-implied price, is $2.70 a share on this run. The fair value weighs that against the company's own multiple.
All oil & gas equipment & services stocks ranked by gap to fair value
Core Laboratories at a glance
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction.
- Market value
- $417M
- Sector
- Energy
- Industry
- Oil & Gas Equipment & Services
- Revenue expected, next twelve months
- $524M
- Consensus revenue growth, next fiscal year
- -3.2%
- Analysts with estimates
- 2
- Beta to the US market
- 1.01
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CLB was not among them.
How the fair value is worked out: the model prices Core Laboratories on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CLB was $7.96. As of 14 Nov 2026 it is $8.21, a change of +3.1%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Core Laboratories's valuation
Is Core Laboratories stock undervalued or overvalued?
On Faircurve's model, CLB reads as Fairly valued as of 14 Nov 2026. The model's fair value is $8.21 a share against a last close of $8.45, a gap of -2.8%.
What is CLB's fair value?
$8.21 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $5.90 to $10.97.
What price range does the model give CLB?
$6.57 to $9.75 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Core Laboratories report earnings next?
The next report is scheduled for 3 Feb 2027. Companies can move their dates.
How much has CLB moved on past earnings reports?
Across its last 8 reports the median two session move was 7.1%, ignoring direction. The largest was +36.6% around the report of 22 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for CLB is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CLB
The model holds no idea open on CLB today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CLB with their outcomes. A free account is enough.